Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Bain

Showing results (421-430 of 494) with videos related to

Pageof 50
Sort By:
Lancet (London, England)|November 23, 2025
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trialDeborah B Horn, Donna H Ryan, Sanja Giljanovic Kis, et al.
Nature Communications|June 14, 2016
Long-lived self-renewing bone marrow-derived macrophages displace embryo-derived cells to inhabit adult serous cavitiesCalum C Bain, Catherine A Hawley, Hannah Garner, et al.
Drugs|June 23, 2021
Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 InhibitorsMarc Evans, Angharad R Morgan, Zaheer Yousef, et al.
Annals of Human Genetics|March 14, 2001
Conditional ETDT analysis of the human leukocyte antigen region in type 1 diabetesB P Koeleman, M H Herr, P Zavattari, et al.
Diabetes, Obesity & Metabolism|August 4, 2020
Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trialsSubodh Verma, Darren K McGuire, Stephen C Bain, et al.
Diabetes Research and Clinical Practice|August 13, 2011
Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitusJ W Stephens, T B Bodvarsdottir, K Wareham, et al.
Mucosal Immunology|August 21, 2014
CCR2(+)CD103(-) intestinal dendritic cells develop from DC-committed precursors and induce interleukin-17 production by T cellsC L Scott, C C Bain, P B Wright, et al.
Mucosal Immunology|February 2, 2017
Tissue-specific differentiation of colonic macrophages requires TGFβ receptor-mediated signalingA Schridde, C C Bain, J U Mayer, et al.
The Lancet. Diabetes & Endocrinology|March 4, 2021
Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trialMatthias von Herrath, Stephen C Bain, Bruce Bode, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|April 5, 2024
SGLT2 Inhibitors - The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative ReviewSamuel Seidu, Vicki Alabraba, Sarah Davies, et al.
Pageof 50

Showing results (421-430 of 494) with videos related to

Sort By:
Pageof 50
Lancet (London, England)|November 23, 2025
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trialDeborah B Horn, Donna H Ryan, Sanja Giljanovic Kis, et al.
Nature Communications|June 14, 2016
Long-lived self-renewing bone marrow-derived macrophages displace embryo-derived cells to inhabit adult serous cavitiesCalum C Bain, Catherine A Hawley, Hannah Garner, et al.
Drugs|June 23, 2021
Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 InhibitorsMarc Evans, Angharad R Morgan, Zaheer Yousef, et al.
Annals of Human Genetics|March 14, 2001
Conditional ETDT analysis of the human leukocyte antigen region in type 1 diabetesB P Koeleman, M H Herr, P Zavattari, et al.
Diabetes, Obesity & Metabolism|August 4, 2020
Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trialsSubodh Verma, Darren K McGuire, Stephen C Bain, et al.
Diabetes Research and Clinical Practice|August 13, 2011
Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitusJ W Stephens, T B Bodvarsdottir, K Wareham, et al.
Mucosal Immunology|August 21, 2014
CCR2(+)CD103(-) intestinal dendritic cells develop from DC-committed precursors and induce interleukin-17 production by T cellsC L Scott, C C Bain, P B Wright, et al.
Mucosal Immunology|February 2, 2017
Tissue-specific differentiation of colonic macrophages requires TGFβ receptor-mediated signalingA Schridde, C C Bain, J U Mayer, et al.
The Lancet. Diabetes & Endocrinology|March 4, 2021
Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trialMatthias von Herrath, Stephen C Bain, Bruce Bode, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|April 5, 2024
SGLT2 Inhibitors - The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative ReviewSamuel Seidu, Vicki Alabraba, Sarah Davies, et al.
Pageof 50